CSL Behring News)

Global Newsroom

Recent News Releases

For investor-related news, see our ASX releases on our parent company's website: CSL.com.

COVID-19 Update
11 Sep 2020

CSL continues to provide medicines to patients around the world.

CSL Behring Continues to Support Alpha 1 Community, Presents Exciting, New Drug Development Projects at 30th Anniversary of the European Respiratory Society International Congress
04 Sep 2020

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
30 Jul 2020

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

CSL Behring’s Global Role in Battling COVID-19
14 Jul 2020

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress
09 Jul 2020

KING OF PRUSSIA, Pa.

• Five coagulation researchers named this year’s recipients
• Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
06 Jul 2020

KING OF PRUSSIA, Pa.

- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
- CSL Behring now evaluating 5 approaches to preventing and treating COVID-19

CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
24 Jun 2020

KING of PRUSSIA, Pa.

• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
• CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
12 Jun 2020

King of Prussia, Pa

Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema
08 Jun 2020

HATTERSHEIM, Germany

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

CSL Behring to Acquire Biotech Company Vitaeris
08 Jun 2020

KING OF PRUSSIA, Pa

• Builds on CSL Behring’s promise and commitment to the transplant community
• Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio

CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
02 Jun 2020

SEATTLE and KING of PRUSSIA, Pa.

Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)

Thermo Fisher Scientific and CSL Enter Strategic Partnership
27 May 2020

WALTHAM, Mass. and KING OF PRUSSIA, Penn.

Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation
26 May 2020

Redmond, Wash., USA, and New York

“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
07 May 2020

Osaka, JAPAN, and King of Prussia, PA, USA

- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach

- Alliance urges anyone who has recovered from COVID-19 to consider donating today

CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)
21 Apr 2020

KING OF PRUSSIA, Pa.

Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
08 Apr 2020

King of Prussia, Pa. and Sioux Falls, S.D.

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
06 Apr 2020

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
13 Feb 2020

Philadelphia, Pa

Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
11 Feb 2020

KING OF PRUSSIA, Pa

CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease

Resources for Media

Fact Sheet           

At-a glance Facts and Figures About CSL Behring    

Brand Center           

Logos, Design Guidelines and more. (Registration required)

Brochure           
See how we are Driven by Our Promise in our 16-page Corporate Brochure.                        

CSL Behring Media Contacts

Natalie de Vane

Corporate Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4468

Jennifer Purdue

Hematology, Respiratory and Transplant Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4802

Dana Lynch

Immunology Inquiries
King of Prussia, PA, USA
Phone: +1 610-878-4545

Faraz Kermani

Corporate Inquiries, Europe
Hattersheim am Main, Hesse, Germany
Phone: +49 69 305 17169

CSL Behring Production Sites

Sandra Ruckstuhl

Bern, Switzerland
Phone: +41 31-344-1124

Maureen E. Powell

Kankakee, Illinois, USA
Phone: +1 815-935-3120

Stephanie Fuchs

Marburg, Germany
Phone: +49 151 58438860

Christina Hickie

Broadmeadows, Victoria, Australia
Phone: +61 429 609 762

CSL Plasma:
For any CSL Plasma corporate or donation inquiries, please refer to the CSL Plasma website for more information.

Archived News Releases